<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595750</url>
  </required_header>
  <id_info>
    <org_study_id>CIB-ROF-2011-01</org_study_id>
    <secondary_id>2011-005047-27</secondary_id>
    <nct_id>NCT01595750</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>REVASC</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Research Center for Respiratory Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Research Center for Respiratory Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      REVASC is a randomized, double-blind, placebo-controlled study which will involve 150
      patients with chronic bronchitis and COPD diagnosed cardiovascular disease. The recruitment
      period beginimg in the coming weeks, will last nine months. Patients included in the study
      will receive treatment for three months with roflumilast 500 mg (75 patients) or placebo (75
      patients) in a randomized manner. The CIBERES, as promoter of this study is expected to
      release final results for the third quarter of 2013.

      Eight centers in Madrid will be involved in this clinical trial: Fundación Jiménez Díaz,
      Hospital La Princesa, Hospital Gregorio Maranon Hospital Clinico San Carlos, Hospital La Paz,
      Hospital Ramón y Cajal Hospital Doce de Octubre and Hospital Puerta del Hierro.

      Roflumilast is a potent phosphodiesterase-4 inhibitor (PDE4). Its clinical efficacy has been
      studied in an extensive clinical program involving over 12,000 patients with COPD. In these
      studies, roflumilast (in combination with long-acting bronchodilators) reduced the number of
      exacerbations and improved lung function, especially in those patients with associated
      chronic bronchitis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endotelial function</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial siffness</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and plasma inflammation markers: (CRP, fibrinogen, leucocytes, interleukin (IL)-8, IL-6, IL-10, tumor necrosis factor alpha (TNFα), sICAM-1, MCP-1, PARC/CCL-18)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum oxidatrive stress markers: MPO, TRX</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum endothelial dysfunction markers:TWEAKs, FasL, ADMA</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roflumilast 500 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast 500</intervention_name>
    <description>Roflumilast 500 mcg , 12 weeks of treatment</description>
    <arm_group_label>Roflumilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 500 mcg , 12 weeks of treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  55-75 years of age

          -  Current and former smokers &gt;20 cigarettes pack-yr (if former smokers withdrawn &gt;1
             year)

          -  Diagnosis COPD (GOLD criteria1 for more than a year before V0)

          -  Presence of chronic bronchitis (cough and/or expectoration for more that 3 months/yr
             for more than 2 consecutive yrs. in the absence of other potential cause)

          -  Post-bronchodilator FEV1&lt;70% reference

          -  Presence of established CVD, CVD equivalent or diabetes mellitus

          -  Presence of chronic systemic inflammation, determined on:

               1. Serum CRP ≥ 2 and &lt; 10 mg/l or

               2. Serum fibrinogen &gt; 518 mg/dl and Leucocytes &gt; 8,6*106 /mm3

        Exclusion Criteria:

          -  Episode of COPD exacerbation and/or COPD treatment change during the last 2 months
             before V0

          -  History of asthma, significant residual lung lesions or bronchiectasis on chest x-ray

          -  Apnea-hypopnea syndrome

          -  Poorly controlled CVD risk factors (Table 2) and/or change in their treatment during
             the last 3 months before V0

          -  Clinically significant cardiac arrhythmias or valve disease

          -  Severe concomitant immunological, inflammatory, infectious or neoplastic diseases

          -  Moderate or severe hepatic insufficiency (B or C class, following Child-Pugh scale)

          -  Severe neurologic and/or psychiatric disorder, including depression with suicidal
             ideas

          -  Alcohol and/or drug abuse during the last 12 months before V0

          -  Hypersensitivity to roflumilast or to any of its excipients

          -  Pregnancy or potential pregnancy

          -  Participation in other clinical trial during the last 30 days before V0

          -  Language difficulties to follow the instructions of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Ancochea</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Álvarez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Doce de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar De Lucas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myriam Calle</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvador Díaz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco García</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Malo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Germán Peces-Barba</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Jiménez Díaz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Àlvar Agustí</last_name>
    <phone>971 011 772</phone>
    <email>info@ciberes.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paloma Vaquer</last_name>
    <phone>971 011 772</phone>
    <email>pvaquer@ciberes.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spanish Research Center for Respiratory Diseases</name>
      <address>
        <city>Bunyola</city>
        <state>Balearic Island</state>
        <zip>07110</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paloma Vaquer</last_name>
      <phone>0034971011772</phone>
      <email>pvaquer@ciberes.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>May 9, 2012</last_update_submitted>
  <last_update_submitted_qc>May 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-bronchodilator FEV1&lt;70% reference</keyword>
  <keyword>Chronic bronchitis</keyword>
  <keyword>Presence of estavlished CVD,</keyword>
  <keyword>CVD equivalent or diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

